Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
Status
RECRUITING
Phase
NA
Age
≥ 18 Years
Enrollments
60Conditions
Prostate CancerSummary
The purpose of this research is to gather information on the safety and effectiveness of using an imaging technique called magnetic resonance imaging (MRI) to decrease radiation dose to the uninvolved prostate (areas of the prostate that do not clearly have cancer cells) while increasing radiation dose to the nodules (hardened areas of the prostate that have cancer cells).
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Clinical Trials Intake
- 855-702-8222
- [email protected]
Principal Investigator
- Stanley Liauw
Eligibility Criteria
Inclusion Criteria:
* Adult (≥ 18 years old) male patients with an ECOG Performance Status 0-2
* Histologically-confirmed, MRI-visible prostate adenocarcinoma with NCCN intermediate- or high-risk disease1 without extra-pelvic metastasis.
Exclusion Criteria:
* Distant metastases
* Prior active treatment for prostate cancer including radical prostatectomy, high-intensity focused ultrasound (HIFU), cryosurgery, ADT, or cytotoxic chemotherapy for treatment of prostate cancer. Patients with prostate cancer on active surveillance prior to the study are not excluded if they have not received active treatment.
* Prior pelvic radiotherapy including brachytherapy.
* Additional active concurrent malignancies (except localized cutaneous squamous or basal cell carcinomas).
* Comorbid conditions that, in the opinion of the treating radiation oncologist, preclude the patient from safely receiving the protocol-specified treatment including RT and/or ADT.
* Patients with contraindications to MRI including patients with ferromagnetic materials in their body (e.g. bioimplants, surgical hardware, shrapnel), patients who are unable to receive contrast due to history of allergy or impaired renal function (glomerular filtration rate < 30 mil/min), and patients unable to tolerate MRI for other reasons (e.g. significant claustrophobia).
* Patients for whom hydrogel or hyaluronic acid spacer will be placed.
* Patients incapable of giving informed consent.
* Patients who are unable to adhere to the experimental protocols for any reason.
Study Plan
Radiation therapy
EXPERIMENTAL
Participants will receive MRI scan before starting Radiation treatment. The results of this scan will be used to identify areas of the prostate to receive low doses of radiation (areas that show no cancer cells seen by the MRI scan).
RADIATION:
RadiationDescription:
Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.RADIATION:
MRIDescription:
The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.OTHER:
Androgen Deprivation TherapyDescription:
Treatment of treating physician choice will be given for 6-24 months.
Outcome Measures
Primary Outcome Measures
Improvement in bowel related quality of life
Secondary Outcome Measures
Biochemical control
Relationship between Imaging findings and Pathologic (tissue) findings
Treatment Side effects
Patient reported quality of life
Timeline
Last Updated
July 31, 2024Start Date
December 14, 2023Today
January 16, 2025Completion Date ( Estimated )
October 20, 2028
Sponsors of this trial
Lead Sponsor
University of Chicago
RECRUITING 
21 - 64 Years